

Curriculum Vitae

- **Name:** Tai-Gyu Kim, MD, PhD, Professor

- **Current Position:** Catholic Hematopoietic Stem Cell Bank, Department of Microbiology, College of Medicine, The Catholic University of Korea

- **E-mail:** kimtg@catholic.ac.kr

- **Educational Background:**

M.D., College of Medicine, The Catholic University of Korea, 1983

Ph.D., College of Medicine, The Catholic University of Korea, 1991

- **Professional Experiences:**

2009.3 - : Chair, Department of Microbiology, College of Medicine, The Catholic University of Korea

2002. 9- : Director, Catholic Hemopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea

2003. 2- : Professor, Department of Microbiology, College of Medicine, The Catholic University of Korea

1995. 3 - 1997. 2 : Research Fellow, St. Jude Children's Research Hospital, TN, USA

- **Professional Organizations**

Board member of The Korean Association of Immunologists

Board member of Korean Society of Microbiology

President of Korean Dendritic Cell Academic Society

Member of The Korean Society of Hematology

- **Main Scientific Publications:**

1. Comprehensive Analysis of CD4⁺ T Cell Responses to CMV pp65 Antigen Restricted by Single HLA-DR, -DQ, and -DP Allotype Within an Individual. *Front Immunol.* 2021 Feb 15;11:602014.
2. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity. *Cancer Res Treat.* 2020 Jul;52(3):747-763.
3. GM-CSF Promotes the Expansion and Differentiation of Cord Blood Myeloid-Derived Suppressor Cells, Which Attenuate Xenogeneic Graft-vs.-Host Disease. *Front Immunol.* 2019 Feb 26;10:183.
4. Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial. *Bone Marrow Transplant.* 2019 Jun;54(6):903-906.
5. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy. *Br J Cancer.* 2018 Feb 20;118(4):534-545.
6. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases. *Int J Hematol.* 2018 May;107(5):596-603.
7. Comprehensive Analysis of Cytomegalovirus pp65 Antigen-Specific CD8(+) T Cell Responses According to Human Leukocyte Antigen Class I Allotypes and Intraindividual Dominance. *Front Immunol.* 2017, 21;8:1591.

8. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia. *Oncotarget*. 2017, 4;8(27):44059-44072.
9. Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy. *Oncotarget*. 2016, 19;7(29):46173-46186.
10. Triple costimulation via CD80, 4-1BB, and CD83 ligand elicits the long-term growth of V γ 9V δ 2 T cells in low levels of IL-2. *J Leukoc Biol*. 2016, 99(4):521-9.
11. An optimized peptide vaccine strategy capable of inducing multivalent CD8(+) T cell responses with potent antitumor effects. *Oncoimmunology*. 2015, 26;4(11): e1043504.
12. Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs. *Mol Ther*. 2015, 23(8):1401-9.